The Center for Immuno-Oncology (CIO) Translational Research area at the National Cancer Institute functions as a multidisciplinary and interdisciplinary translational research programmatic effort with the goal of developing novel immunotherapies and immunotherapeutic strategies for cancer. Focus is placed on the development of novel immunotherapeutics, not only as monotherapies, but more importantly, in combination with other immune-mediating modalities, and other conventional or experimental therapies, as part of an immuno-oncology programmatic effort. Within this effort are several research groups which interact closely with the clinical groups of the CIO, and with collaborators within the NCI intramural and extramural programs, and with investigators in the private sector. As Co-Director of the CIO, Dr. Jeffrey Schlom directs the Translational Research area of investigation.
The program takes advantage of the uniqueness of the NCI intramural program in that it spans high-risk basic discovery research in immunology genomics and tumor biology, through preclinical translational research, to paradigm-shifting clinical trials. Focus is placed on the design and development of novel ‘off-the-shelf’ recombinant (rec.) immunotherapeutics that can be used in clinical studies at numerous institutions. A major strength of the program is the rapid translation of preclinical studies to hypothesis-generating clinical trials.
We are looking for post-doctoral fellows interested in learning immunology and immunotherapy. The position is available immediately. The appointment duration is up to 5 years. Stipends are commensurate with education and experience. Experience Required: Ph.D., M.D. or equivalent in immunology, molecular/cell biology or experimental pathology
To apply, please send a cover letter describing your research experience and interests, CV including bibliography, and contact information for three references to:
Jeffrey Schlom, Ph.D., via e-mail: firstname.lastname@example.org.
No calls, please. If we are interested, you will be contacted by Dr. Schlom.